Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035714 | 0.83 | KMT2A (0.37) | HTR2CHTR2AHTR2BKIF11 | |
| SCHEMBL4041534 | 0.81 | GRIN2B (0.39) | KIF11 | |
| SCHEMBL4035392 | 0.81 | GID4 (0.45) | — | |
| SCHEMBL29746117 | 0.80 | HTR2C (0.48) | HTR2CHTR1APBRM1HTR2AHTR2B | |
| SCHEMBL4033053 | 0.80 | MEN1 (0.41) | — | |
| SCHEMBL26613523 | 0.80 | HTR2C (0.48) | HTR2CHTR1APBRM1HTR2AHTR2B | |
| SCHEMBL4037803 | 0.79 | CETP (0.39) | — | |
| SCHEMBL4033171 | 0.79 | CETP (0.39) | — | |
| SCHEMBL4035393 | 0.79 | CETP (0.39) | — | |
| SCHEMBL4036036 | 0.77 | KDM4E (0.46) | HTR2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928238-B2 | 1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7928238-B2 | 1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| EP-2034998-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008079427-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079427-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-03 | — | — | WO | disclosed |
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | CETP, NPC1, CES1 | HTR2C 2512/4885HTR1A 1831/4885PBRM1 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.